ND: |
ME12192262 |
PMID: |
12192262 |
LR: |
20051117 |
CED: |
20020822 |
DCO: |
20030128 |
Autoren: |
Jubb RW |
Titel: |
Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002. |
Quelle: |
Current opinion in rheumatology; VOL: 14 (5); p. 597-602 /200209/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
United States |
JID: |
9000851 |
ISSN: |
1040-8711 |
CO: |
CORHES |
Institution: |
University of Birmingham, Selly Oak Hospital, UK. Ronald.jubb@uhb.nhs.uk |
DT: |
Journal Article; Review |
RN: |
45 |
Schlagwörter |
CT: |
ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; ANTIRHEUMATIC AGENTS/administration & dosage; ANTIRHEUMATIC AGENTS/*therapeutic use; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS/adverse effects; HUMANS; HYPERTENSION/chemically induced; INJECTIONS, INTRA-ARTICULAR; ISOENZYMES/antagonists & inhibitors; MEMBRANE PROTEINS; OSTEOARTHRITIS/*drug therapy; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES |
CTG: |
APPLIKATION, ORALE; ALTE MENSCHEN; ALTE MENSCHEN, 80 JAHRE UND ÄLTER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; ANTIRHEUMATIKA/Verabreichung & Dosierung; ANTIRHEUMATIKA/*therapeutische Anwendung; CYCLOOXYGENASE 2; CYCLOOXYGENASE-2-INHIBITOREN; CYCLOOXYGENASEINHIBITOREN/unerwünschte Nebenwirkungen; MENSCH; HYPERTONIE/chemisch hervorgerufen; INJEKTIONEN, INTRAARTIKULÄRE; ISOENZYME/Antagonisten & Inhibitoren; MEMBRANPROTEINE; OSTEOARTHROSE/*Arzneimitteltherapie; PROSTAGLANDIN-ENDOPEROXID-SYNTHASE |
TE: |
Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Membrane Proteins; Cyclooxygenase 2/E.C. 1.14.99.1; PTGS2 protein, human/E.C. 1.14.99.1; Prostaglandin-Endoperoxide Synthases/E.C. 1.14.99.1 |
CR: |
E.C. 1.14.99.1; E.C. 1.14.99.1; E.C. 1.14.99.1 |
AB: |
There have been considerable advances in the drug treatments used to treat osteoarthritis. The development of selective cyclo-oxygenase inhibitors (COX-II) and confirmation of their efficacy and gastrointestinal safety will reduce treatment morbidity in the elderly. Guidelines for safe and appropriate use of COX-II drugs are now available. The role of anti-inflammatory drugs in precipitating cardiorenal events has been highlighted but remains to be fully evaluated. Glucosamine, diacerein, and hyaluronan may all be disease-modifying drugs for osteoarthritis but confirmatory studies are still needed. |